‌[微笑] ‌_老虎社区_美港股上老虎 - 老虎社区

1
评论
收藏

海熊
06-04

‌[微笑] ‌

礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振

近期利好频传。

礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

1

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":571649862169064,"tweetId":"571649862169064","gmtCreate":1780587223802,"gmtModify":1780587804954,"author":{"id":3455015162490195,"idStr":"3455015162490195","authorId":3455015162490195,"authorIdStr":"3455015162490195","name":"海熊","avatar":"https://static.laohu8.com/23daf95ed79ce1d13a339b23c054df16","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":"93.92%","individualDisplayEnabled":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>‌<a href=\"\">[微笑]&nbsp;</a>‌</body></html>","htmlText":"<html><head></head><body>‌<a href=\"\">[微笑]&nbsp;</a>‌</body></html>","text":"‌[微笑] ‌","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/571649862169064","repostId":1185465612,"repostType":2,"repost":{"id":"1185465612","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1780585052,"share":"https://www.laohu8.com/m/news/1185465612?lang=zh_CN&edition=full","pubTime":"2026-06-04 22:57","market":"us","language":"zh","title":"礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1185465612","media":"异动解读","summary":"近期利好频传。","content":"<html><head></head><body><p style=\"text-align: left;\">周四，美股“减肥药双雄”盘中同步拉升，<a href=\"https://laohu8.com/S/LLY\">礼来</a>、<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>均涨逾5%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c3c1bbf68376f4d55fc285db89b05d6\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6f146edd5384465780d9466f42251878\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p style=\"text-align: left;\">消息面上，礼来宣布了一系列战略举措，包括拟以70亿美元收购Kelonia布局体内CAR-T领域，与Ascidian签署高达19亿美元的RNA编辑协议，以及与海思科达成30.5亿美元的药物发现合作。同时，公司在研发管线方面取得积极进展，其下一代减重疗法retatrutide在肥胖症3期临床试验中展现显著效果，抗癌药物Retevmo也公布了降低肺癌患者疾病风险的强劲数据。此外，公司广受欢迎的GLP-1减肥药Zepbound和口服药物Foundayo的市场准入范围正在扩大，已被美国主要药品福利管理机构纳入承保。</p><p style=\"text-align: left;\"><span>诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。司美格鲁肽前三季度销售额约254.62亿美元，同比增长24%，基本面支撑股价反弹。</span></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2026-06-04 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">周四，美股“减肥药双雄”盘中同步拉升，<a href=\"https://laohu8.com/S/LLY\">礼来</a>、<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>均涨逾5%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c3c1bbf68376f4d55fc285db89b05d6\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6f146edd5384465780d9466f42251878\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p style=\"text-align: left;\">消息面上，礼来宣布了一系列战略举措，包括拟以70亿美元收购Kelonia布局体内CAR-T领域，与Ascidian签署高达19亿美元的RNA编辑协议，以及与海思科达成30.5亿美元的药物发现合作。同时，公司在研发管线方面取得积极进展，其下一代减重疗法retatrutide在肥胖症3期临床试验中展现显著效果，抗癌药物Retevmo也公布了降低肺癌患者疾病风险的强劲数据。此外，公司广受欢迎的GLP-1减肥药Zepbound和口服药物Foundayo的市场准入范围正在扩大，已被美国主要药品福利管理机构纳入承保。</p><p style=\"text-align: left;\"><span>诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。司美格鲁肽前三季度销售额约254.62亿美元，同比增长24%，基本面支撑股价反弹。</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/383539e68cf14d4cde7a90d97b6a4424","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","LLY":"礼来","NVO":"诺和诺德","NVOH":"Novo Nordisk A/S B Shares ADRhedged"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185465612","content_text":"周四，美股“减肥药双雄”盘中同步拉升，礼来、诺和诺德均涨逾5%。消息面上，礼来宣布了一系列战略举措，包括拟以70亿美元收购Kelonia布局体内CAR-T领域，与Ascidian签署高达19亿美元的RNA编辑协议，以及与海思科达成30.5亿美元的药物发现合作。同时，公司在研发管线方面取得积极进展，其下一代减重疗法retatrutide在肥胖症3期临床试验中展现显著效果，抗癌药物Retevmo也公布了降低肺癌患者疾病风险的强劲数据。此外，公司广受欢迎的GLP-1减肥药Zepbound和口服药物Foundayo的市场准入范围正在扩大，已被美国主要药品福利管理机构纳入承保。诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。司美格鲁肽前三季度销售额约254.62亿美元，同比增长24%，基本面支撑股价反弹。","news_type":1,"symbols_score_info":{"NVO":2,"NVOH":0.6,"NVOX":0.6,"LLY":1}},"isVote":1,"tweetType":1,"viewCount":334,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}